ROCKVILLE, Md.--(BUSINESS WIRE)--Celera (NYSE: CRA), an Applera Corporation business, and its collaborators at the Cleveland Clinic, University of California, San Francisco (UCSF), the Scripps Institute, and Queens University, Canada, today announced the publication of a paper describing a novel variant of the LPA gene that is associated with an approximate 3-fold increased risk of severe coronary artery disease (CAD). The paper is scheduled to appear in the September 2007 edition of Arteriosclerosis, Thrombosis and Vascular Biology, and is currently available on the journal’s website at http://atvb.ahajournals.org/. The lead author of the paper was May Luke, Ph.D., Staff Scientist, Cardiovascular Diseases, at Celera.
